Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.71 SEK | -0.70% | -8.79% | +2.33% |
Sales 2024 * | 65.08M 5.96M 476M | Sales 2025 * | 471M 43.11M 3.44B | Capitalization | 1.68B 154M 12.3B |
---|---|---|---|---|---|
Net income 2024 * | -291M -26.64M -2.13B | Net income 2025 * | 105M 9.61M 768M | EV / Sales 2024 * | 27.4 x |
Net Debt 2024 * | 103M 9.39M 750M | Net cash position 2025 * | 61.97M 5.67M 453M | EV / Sales 2025 * | 3.44 x |
P/E ratio 2024 * |
-6.05
x | P/E ratio 2025 * |
8.41
x | Employees | 28 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.61% |
Latest transcript on Egetis Therapeutics AB
1 day | -0.70% | ||
1 week | -8.79% | ||
Current month | -14.52% | ||
1 month | -15.53% | ||
3 months | -5.93% | ||
6 months | +21.36% | ||
Current year | +2.33% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 15/06/17 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 45 | 30/12/17 |
Chief Tech/Sci/R&D Officer | - | 04/05/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mats Blom
BRD | Director/Board Member | 59 | 31/03/21 |
Director/Board Member | 50 | 31/12/19 | |
Thomas Lönngren
CHM | Chairman | 73 | 31/03/21 |
Date | Price | Change | Volume |
---|---|---|---|
29/04/24 | 5.71 | -0.70% | 86 169 |
26/04/24 | 5.75 | -3.20% | 568,552 |
25/04/24 | 5.94 | +0.17% | 152,280 |
24/04/24 | 5.93 | -5.57% | 271,959 |
23/04/24 | 6.28 | +0.32% | 137,986 |
Delayed Quote Nasdaq Stockholm, April 29, 2024 at 10:00 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.33% | 153M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+0.79% | 22.15B | |
-17.37% | 21.02B | |
-7.98% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- EGTX Stock